Accelerating AML and MDS Treatment Strategies with Rapid NGS in the myeloMATCH Trial

Rapid Genomic Profiling

In the era of precision oncology, genomic profiling plays a crucial role in the assessment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

However, traditional genomic analysis using next-generation sequencing (NGS) can be time-consuming, taking weeks to provide results and potentially leading to delays in treatment decisions. Rapid NGS testing addresses this challenge through workflow automation, which enables laboratories to generate a comprehensive molecular profile with next-day results. The data obtained from rapid NGS can inform front-line treatment decisions and facilitate swift patient enrollment into clinical studies.

The NCI Myeloid Assay -based on Ion Torrent and Oncomine technology

Rapid NGS testing has recently been implemented as part of the myeloMATCH trial, which is the National Cancer Institute's (NCI's) precision medicine umbrella trial for AML and MDS patients.

Through this approach, patients can be assigned to a sub-study within 72 hours of the lab receiving the sample, allowing timely therapy initiation.

At the heart of the myeloMATCH molecular testing strategy is the NCI Myeloid Assay, ran on the Ion Torrent Genexus system. This NGS test enables a comprehensive molecular analysis of DNA mutations and RNA fusions, with results available within 72 hours for patient enrollment. With rapid NGS, there is great potential for helping to  improve patient outcomes and expediting the availability of new therapies. 

Notably, the myeloMATCH program, including the use of Ion Torrent and Oncomine technology for the NCI Myeloid Assay, has received Investigational Device Exemption (IDE) and Investigational New Drug (IND) authorization.

NCI Myeloid Assay Performance Data 

View this presentation by Dr. Cecilla Yeung to see performance data from the NCI Myeloid Assay with the Ion Torrent Genexus System. 

Cecilia Yeung, MD
Associate Professor
Clinical Research Division,
Fred Hutch Cancer Center

AMP 2023 Corporate Workshop:
Rapid NGS for Genomic Profiling of Myeloid Malignancies

ASH 2023 Scientific Poster: Rapid Clinical Mutation Screening for AML Using the Genexus Platform

See recent performance data for the NCI Myeloid Assay v2, showing high specificity, sensitivity, accuracy, and reproducibility (inter-lab and intra-lab) with sequencing results generated within 48 hours of assay initiation². Read Abstract

> View Poster

Accelerating Treatment Strategies

myeloMATCH is open through the NCI National Clinical Trials Network in the United States and Canada, encompassing over 2,200 sites.

Cooperative research and development agreements with various pharmaceutical companies will enable access to a range of different drugs to support the myeloMATCH trial.

By conducting multiple treatment sub-studies tailored to specific genomic types, myeloMATCH has the potential to drive the advancement of exciting new therapies.

Learn more about myeloMATCH at the following websites below.

myeloMATCH Overview by SWOG  |  myeloMATCH Overview by NCI  |  ClinicalTrials.gov

Ready to speak to a Thermo Fisher Representative?

We will be happy to answer your questions and provide a demo of our NGS solutions.

NCI has validated Genexus for investigational use within the MyeloMatch study. Genexus is currently available in the North America for research use only. Not for use in diagnostic procedures.

References 
1. Richard F. Little, et al. Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative. Blood (2022) 140 (Supplement 1): 9057–9060.
2. Shahanawaz Jiwani, et al. Clinical Mutation Screening for AML Using the Genexus Platform. 65th ASH Annual Meeting and Exposition (Poster Presentation) 

Case Number 55239 (0724)